公开(公告)号：US20060135608A1

公开(公告)日：2006-06-22

申请号：US10528114

申请日：2003-09-16

Applicant: David Horrobin ,  Agnes Ayton ,  Sherri Clarkson

Inventor： David Horrobin ,  Agnes Ayton ,  Sherri Clarkson

IPC: A61K31/202

CPC classification number: A61K31/202

Abstract: Eicosapentaenoic acid (EPA) is used in the treatment of anorexia nervosa, bulimia and related clinical syndromes.

Abstract translation: 二十碳五烯酸（EPA）用于治疗神经性厌食症，贪食症及相关临床综合征。

公开(公告)号：US20070197644A1

公开(公告)日：2007-08-23

申请号：US11783494

申请日：2007-04-10

Applicant: Michael Buchanan ,  David Horrobin

Inventor： Michael Buchanan ,  David Horrobin

IPC: A61K31/22 ,  A61K31/202

CPC classification number: A61K47/44 ,  A61K31/00 ,  A61K31/201 ,  A61K31/355 ,  A61K31/375 ,  A61K31/66 ,  A61K31/685 ,  A61K47/14 ,  Y02A50/411 ,  Y02A50/415 ,  A61K2300/00

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

Abstract translation: 本发明涉及在血管壁功能障碍和/或损伤后血管内皮生物相容性的调节和血管壁细胞和其他类型的细胞增生的抑制。 更具体地说，本发明涉及13-羟基十八碳-9Z，11E-二烯酸（13-HODE）的饮食和药物制剂及其在减少或抑制血管壁增生和恢复血管壁生物相容性中的用途。

公开(公告)号：US07202276B2

公开(公告)日：2007-04-10

申请号：US09833257

申请日：2001-04-09

Applicant: Michael Buchanan ,  David Horrobin

Inventor： Michael Buchanan ,  David Horrobin

IPC: A61K31/355 ,  A61K31/375 ,  A61K31/202

CPC classification number: A61K47/44 ,  A61K31/00 ,  A61K31/201 ,  A61K31/355 ,  A61K31/375 ,  A61K31/66 ,  A61K31/685 ,  A61K47/14 ,  A61K2300/00

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

公开(公告)号：US20050209329A1

公开(公告)日：2005-09-22

申请号：US11128401

申请日：2005-05-13

Applicant: David Horrobin

Inventor： David Horrobin

IPC: A61K45/00 ,  A61K31/19 ,  A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/405 ,  A61K31/415 ,  A61P1/04 ,  A61P3/00 ,  A61P3/10 ,  A61P5/24 ,  A61P9/10 ,  A61P11/06 ,  A61P13/02 ,  A61P13/04 ,  A61P13/12 ,  A61P15/00 ,  A61P17/04 ,  A61P17/06 ,  A61P19/02 ,  A61P19/10 ,  A61P21/02 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/32 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/405 ,  A61K31/415 ,  A61K2300/00

Abstract: The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administration of the fatty acid alone.

Abstract translation: 与COX-1或COX-2或LOX或一种或多种FACL酶的抑制剂一起定义具有确定纯度的必需脂肪酸，优选二十碳五烯酸，与单独使用脂肪酸相比，提供改善的治疗结果 。

公开(公告)号：US4092637A

公开(公告)日：1978-05-30

申请号：US683455

申请日：1976-05-05

Applicant: Donald John Barclay ,  Colin Leonard Bird ,  Michael Henry Hallett ,  David Horrobin Kirkman ,  John Francis Minshull ,  Charles Edward Owen

Inventor： Donald John Barclay ,  Colin Leonard Bird ,  Michael Henry Hallett ,  David Horrobin Kirkman ,  John Francis Minshull ,  Charles Edward Owen

IPC: G04G9/00 ,  C25D11/00 ,  G02F1/163 ,  G09F9/30 ,  G09G3/16 ,  G09G3/19 ,  G09G3/38 ,  G09F9/32

CPC classification number: C25D11/00 ,  G02F1/163 ,  G09G3/16 ,  G09G3/38 ,  G09G2310/0267 ,  G09G2310/0275

Abstract: An electrochromic display device having first and second electrodes, and a plurality of display electrodes, all immersed in a liquid electrolyte. Drive means act to first generate a potential difference between said first and second electrodes to cause a color species to be deposited on said first electrode and, thereafter, act to generate a potential difference between said first electrode and selected ones of said plurality of display electrodes to cause the color species to be transferred to the selected ones of said plurality of display electrodes. Heptyl viologen dibromide is suggested as one possible electrolyte.

公开(公告)号：US20070148643A1

公开(公告)日：2007-06-28

申请号：US10536927

申请日：2003-11-26

Applicant: David Horrobin ,  Sherri Clarkson

Inventor： David Horrobin ,  Sherri Clarkson

IPC: C12Q1/68 ,  A61K31/202

CPC classification number: A61K31/00 ,  A61K31/20 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.

Abstract translation: 亨廷顿病基因分析提供了一种鉴定可能用二十碳五烯酸EPA治疗亨廷顿氏病的患者的方法。

公开(公告)号：US20050147665A1

公开(公告)日：2005-07-07

申请号：US10995533

申请日：2004-11-24

Applicant: David Horrobin ,  Christina Gouaille

Inventor： David Horrobin ,  Christina Gouaille

IPC: A61K9/64 ,  A61K31/122 ,  A61K31/201 ,  A61K31/202 ,  A61K31/232 ,  A61K31/355 ,  A61K31/375 ,  A61K31/409 ,  A61K31/525 ,  A61K31/70 ,  A61P1/00 ,  A61P3/02 ,  A61P3/04 ,  A61P3/10 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P25/00 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61K31/714 ,  A61K31/4415

CPC classification number: A61K31/70 ,  A61K31/505 ,  A61K31/44 ,  A61K31/20 ,  A61K31/23 ,  A61K31/385 ,  A61K31/375 ,  A61K31/355 ,  A61K31/12 ,  A61K2300/00

Abstract: The combined application of at least one essential fatty acid of the n-6 or n-3 series, optionally together with further essential fatty acid(s) of the n-6 or n-3 series, together with one or more homocysteine lowering agent. The homocysteine lowering agent is selected from vitamin B12, folic acid, a compound related to folic acid with similar biological activity and vitamin B6.

Abstract translation: 将n-6或n-3系列的至少一种必需脂肪酸，任选与n-6或n-3系列的其它必需脂肪酸一起连同应用，以及一种或多种同型半胱氨酸降低剂 。 同型半胱氨酸降解剂选自维生素B12，叶酸，与叶酸有相似生物活性的化合物和维生素B6。